IL13 and asthma: Although data on the long-term effects of drugs targeting IL-4, IL-13, or other type 2 cytokines in human are still limited, it is important to note that several large clinical studies are now available for the anti-IL-4Rα mAb with treatment periods from 52 to 96 weeks in both asthma and atopic dermatitis9,46–50.